SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- PURE Bioscience (OTC Bulletin Board: PURE), creators of patented silver dihydrogen citrate (SDC), the active ingredient in a revolutionary new hard surface disinfectant which kills Staph/MRSA as well as other human pathogens, announced that the Company will present at the Biocom Investor Conference on Thursday, November 1, 2007 at the San Diego Marriott Del Mar. Michael L. Krall, CEO, will discuss the Company's patented platform technology, product applications and recent company developments.
SDC is an electrolytically generated source of stabilized ionic silver. A patented new molecular entity, SDC is distinguished from competitors because of its superior efficacy and reduced toxicity. PURE produces and markets ready-to-use EPA-registered disinfectant products, as well as varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third party products, including householder and personal care products. PURE also pursues development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products.
Revolutionary Disinfecting Agent
As previously reported, PURE's EPA registered antimicrobial has
eliminated Staph/MRSA infections in the Tulsa County Jail since that
facility began using the hard surface disinfectant in August 2006. The
jail, with 1,700 cells and more than 1,500 inmates, had historically faced
challenges with Staph. Prior to its use of the SDC disinfectant, the
facility experienced, on average, 12 cases of Staph infection every month.
The first new disinfectant active to be registered by the EPA in more than
30 years, SDC-based products are antiviral, antifungal and antibacterial,
including 24-hour residual protection against standard indicator bacteria
and a 2
|SOURCE PURE Bioscience|
Copyright©2007 PR Newswire.
All rights reserved